ArticleArchives of dermatological research2025

A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS).

Min Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.